Zynex's high P/E ratio is justified by its forecasted growth, outpacing the wider market. Investors anticipate strong future growth, showing less concern for potential earnings deterioration.
Several insiders selling shares over past year could signal a warning for potential investors. High insider ownership, recent selling trends, and lack of insider buying may cause investor caution.
Zynex股票討論區
2023Q1營收增長35.7%,營業利潤大幅萎縮85%,淨利潤增長13.9%。
目前市盈率21.4,市盈率TTM20.9,和近期增速相比折扣不大,可以再觀察一下。
$Spruce Biosciences(SPRB.US)$ $Fate Therapeutics(FATE.US)$ $尚乘數科(HKD.US)$ $Aehr Test Systems(AEHR.US)$ $ATAI Life Sciences(ATAI.US)$ $Immunome(IMNM.US)$ $CytomX(CTMX.US)$ $Sensus Healthcare(SRTS.US)$ $Zynex(ZYXI.US)$ $Graphite Bio(GRPH.US)$
itll bounce back
暫無評論